While a differential effect on the actin cytoskeleton and invasiveness of basal and luminal model cell lines have emerged as an underlying mechanism linked to metastatic behavior, the study of additional mechanisms by which SETD3 acts as a marker of good prognosis in receptor-positive tumors and as a marker for poor prognosis in triple-negative tumors will help us to better understand the role of SETD3 in tumor progression. This evidence concerns the gene SETD3 and neoplasm.